ArticleVirulence2018
Antifungal activity of osthol in vitro and enhancement in vivo through Eudragit S100 nanocarriers.
Article in Virulence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Signaling Pathways Involved in the Neuroprotective Effect of Osthole: Evidence and Mechanisms.Molecular neurobiology · 2024Pooled it
- The novel antifungal agent NPD2560 perturbs the Rho1-centered signaling network to induce a cell wall integrity response.Microbiology spectrum · 2026Article
- Coumarin metabolites in Ocimum: chemical diversity, biosynthetic pathways, and network pharmacology-based prediction of multi-target anticancer potential.Plant molecular biology · 2026Article
- In-vivo Studies on Sustained Release Systems for Delivering Antimycotics. A Systematic Review focused on Oral Candidiasis treatment.Journal of clinical and experimental dentistry · 2025Review
- Therapeutic potential of mesenchymal stem cells for fungal infections: mechanisms, applications, and challenges.Frontiers in microbiology · 2025Review
- The Effect of Osthole on Transient Receptor Potential Channels: A Possible Alternative Therapy for Atopic Dermatitis.Journal of inflammation research · 2024Article
- Antifungal and Immunomodulatory Ingredients from Traditional Chinese Medicine.Antibiotics (Basel, Switzerland) · 2022Review
- Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies.Frontiers in pharmacology · 2022Review
- Osthole Regulates Secretion of Pro-Inflammatory Cytokines and Expression ofJournal of inflammation research · 2022Article
- Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections.eLife · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vitro interaction of osthol (Ost) and fluconazole (FLC) was investigated against 11 fluconazole-resistant clinical isolates of Candida albicans. Synergistic activities were determined using the checkerboard microdilution assay. The results of agar diffusion test confirmed the synergistic interaction. We used an enteric material Eudragit S100 for preparation of Ost nanoparticle (Ost-NP) to improve the oral bioavailability, biological activity of Ost. The physicochemical characteristics of Ost-S100-NP revealed Ost-S100-NP with mean particle size of 55.4±0.4 nm, encapsulation efficiency of 98.95±0.06%, drug loading efficiency of 23.89±0.25%, yield of 98.5±0.1% and a polydispersity index (PDI) of 0.165. As the Ost concentration-time curve showed, Ost-S100-NP can increase the plasma concentration and relative bioavailability of Ost compared with Ost-suspension by oral administration. In vivo, Ost-S100-NP enhanced the therapeutic efficacy of Ost against FLC-resistant C. albicans in immunosuppressed candidiasis mice model. The available information strongly suggests that Ost-S100-NP may be used as a promising compound against drug-resistant fungi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.